Background/Aims: As an "ESKAPE" pathogen, Acinetobacter baumannii is one of the leading causes of drug-resistant infections in humans. Phage therapy may be a useful strategy in treating infections caused by drug-resistant A. baumannii. Among 21 phage strains that were isolated and described earlier, we investigated the therapeutic efficacy of Abp1 because of its relatively wide host range. Methods: Phage stability assays were used to evaluate thermal and pH stability of Abp1. Abp1 was co-cultured with A. baumannii (AB1) over a range of multiplicities of infection to determine its bactericidal efficacy. HeLa or THP-1 cells were used in the cytotoxicity and protection assays. Finally, the therapeutic effects of Abp1 on local and systemic A. baumannii infection in mice were determined. Results: We found that Abp1 exhibits high thermal and pH stability and has a low frequency of lysogeny. Bacteriophage resistance also occurs at a very low frequency (3.51±0.46×10 -8
Introduction
Acinetobacter baumannii (A. baumannii) is a non-fermentative, non-motile, catalasepositive, Gram-negative bacterium [1, 2] , widely found in soil, water, sewage, and many healthcare environments. In clinical settings, this pathogen causes severe pneumonia, as well as infections in the urinary tract, bloodstream, and wounds [2] [3] [4] . In the 1970s, A. baumannii was susceptible to most antibiotics. However, an increasing number of clinical A. baumannii strains now exhibit multi-drug and pan-drug resistance. The rapid development of antibiotic resistance is due to the acquisition of plasmids, transposons, and integrons that carry clusters of genes encoding resistance to several antibiotic families [2, 4] . Effective management of A. baumannii infections has become an increasingly urgent issue, requiring the development of new tools.
A growing body of literature has validated the use of phages for therapy and prophylaxis in the war against drug-resistant bacteria [5] [6] [7] [8] [9] , and many lytic phages have been isolated and tested in animals for their efficacy against bacterial infections. In 2011, the U.S. Food and Drug Administration approved a mixture of bacteriophages as a food additive for protection against foodborne bacterial disease. In addition, promising results have been obtained using phages isolated on-demand to eradicate gram-negative bacteria [10] .
In a previous report we described Abp1, a bacteriophage isolated from hospital sewage [11] . Abp1 is a lytic phage of the pan-drug resistant A. baumannii strain AB1. In this study, we analyzed the potential of Abp1 as a phage therapy candidate and tested its effects in both local and systemic mouse infection models.
Materials and Methods
Bacterial strain and phages A. baumannii AB1 was isolated from a burn patient at Southwest Hospital in Chongqing, China. It is resistant to multiple antibiotics, including aminoglycosides, carbapenems, cephalosporins, tetracyclines, and quinolones, but is sensitive to polymyxin with a MIC of 0.236 mg/L [11] . Abp1 is a lytic phage of AB1, isolated from sewage at the same location. The characteristics of this phage are described in our previous report [11] . Endotoxin was removed from Abp1 cultures using the ToxinEraser endotoxin removal kit (GenScript, China).
Bacteriophage resistance assay
Serial dilutions of A. baumannii AB1, ranging from 10 to 10 9 CFU/ml, were mixed with 5×10 10 plaqueforming units (PFU) of Abp1. 10 µL from each infected culture was spotted onto an agar plate and incubated at 37°C for 24 h. Colonies formed by surviving bacteria were considered to be resistant to Abp1. Bacteriophage resistance was calculated as the ratio of CFU relative to the number of plated bacteria.
Thermal and pH stability of Abp1
To test the thermal stability of Abp1, phage samples (7.5×10
10 PFU in a volume of 1.5 ml) were incubated at 50, 60, 70, and 80 o C. 100 µL aliquots were withdrawn after 5 min, 15 min, 40 min, and 1 h, and diluted 10-fold. 10 μl of diluted phage was combined with 200 μl host bacteria, incubated for 15 minutes, mixed with 3 ml of 0.75% LB agar, and poured onto plates containing solid medium to determine phage titer. For the pH stability assay, aliquots were collected one hour after incubation in liquid media ranging from pH 2 to 13.
Cytotoxicity of Abp1 to HeLa and THP-1 cells
LDH release from HeLa and THP-1 cells was determined using a CytoTox96 cytotoxicity assay (Promega G1780) [12] . HeLa cells were cultured in Dulbecco's Modified Eagle's Medium and THP-1 cells in Roswell Park Memorial Institute 1640 Medium, both supplemented with fetal bovine serum (10%) and penicillin-streptomycin (1%), and incubated in 5% CO 2 at 37°C. When cells reached 70-80% confluence, various amounts of Abp1 were added to the wells. 2% Triton X-100 was added as a positive control, and an equal volume of PBS was used as a negative control. After incubation for 24 hours, 50 µL of supernatant was added to the wells of a 96-well plate containing 50 µL of reaction mixture. The plate was incubated at room temperature for 30 minutes, and then 50 µL Stop Solution was added to halt the reaction. Absorbance was measured at 490 nm. 
Killing (lysis) of AB1 by Abp1 infection at various MOI
To conduct killing assays, an overnight culture of AB1 was diluted 1:100 into 50 ml of medium and incubated for 2 hours at 37 °C to reach a cell density of approximately 5×10
7 CFU/ml (OD 600 =0.5). One milliliter of the culture was added to the wells of a 24-well plate, followed by addition of 100 μl diluted Abp1. To achieve multiplicity of infection (MOI) values of 100, 10, 1, and 0.1, a total of 5×10 9 PFU, 5×10 8 PFU, 5×10 7 PFU and 5×10 6 PFU Abp1 were added to each well. Cell death was analyzed using a microplate reader (SpectraMax M2e, Molecular Devices). The parameters used by SoftMax Pro were as follows: read time interval = 1 hour, with shaking for 50 minutes at 37 °C between reads, for a total of 8 hours. Absorbance at 600 nm was recorded.
HeLa cell infection protection assay
HeLa cells were cultured as described above in 4 wells of a 6-well plate. When cells reached 70-80% confluence, AB1 (10 7 CFU) in 100 µL DMEM medium was added to 2 wells. For the negative controls, DMEM only was added. After 2 hours, Abp1 (10 8 PFU) and an equal volume of PBS were added to all wells. The cells were incubated for additional 22 hours, and the number of living cells was determined using trypan blue.
Phage therapy in a mouse local infection model
The ability of Abp1 to confer protection against AB1 was evaluated using a mouse wound infection model as described previously [13] . Briefly, 36 six-week-old male BALB/c mice were randomly assigned to three groups (n=12 per group). Each mouse received cyclophosphamide (150 mg/kg body weight) via intraperitoneal injection on day -4 and 100 mg/kg on day -1. One day after the second injection, mice were anesthetized with amobarbital sodium and shaved. Two 5.0×5.0 mm full-thickness wounds were created on the dorsal side of each mouse using a skin biopsy punch. 25 μl of PBS containing 5.0×10
4 AB1 cells were deposited on each wound and the region was air-dried for 5 min.
Four hours after infection, mice were inoculated with phage (5.0×10 8 PFU) in PBS either via a subcutaneous injection or by directly pipetting into the wound. Inoculation with PBS alone was used as a negative control. The phage treatments were repeated once a day for 7 days after infection. On days 1, 3, and 7, wound sizes were measured and recorded.
Phage therapy in a systemic mouse infection model
In the mouse systemic infection model, 42 six-week-old male BALB/c mice were randomly assigned to three groups (n=14 per group). 200 μl of PBS containing 5.0×10 7 AB1 cells was injected intraperitoneally into the mice. Immediately after infection, phage (5.0×10 8 PFU) in PBS were injected intraperitoneally on the same side of the mouse used for the bacterial injection. Phage were injected daily for 6 days after infection. Because AB1 is sensitive to polymyxin B, this antibiotic was used as a positive control in the antibiotic treatment group, which received 10 mg/kg polymyxin B daily for 6 days. The same volume of PBS was injected as a negative control in the third group. The animals were monitored for seven days and the survival rate of each group was calculated. During the observation period, dead mice were dissected immediately to obtain the livers and kidneys. 7 days post-infection, survivors were also sacrificed and dissected. For all animals, livers and kidneys were weighed, homogenized in 1 ml saline, serially diluted, and bacterial counts and phage titers were determined.
Ethics statement
All animal experiments complied with the International Guiding Principles for Biomedical Research involving Animals (1985) and were approved by the Laboratory Animal Welfare and Ethics Committee of Southwest Hospital, Third Military Medical University.
Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA) or log-rank test (Mantel-Cox) as appropriate. A value of P < 0.05 was considered significant. 
Results

Characteristics of phage Abp1
Abp1 was isolated from sewage at Southwest Hospital. It has a genome size of 42 kb containing 51 genes, including an endolysin gene [14] as expected for a lytic phage. As shown in Fig. 1A , Abp1 can cause lysis in a bacterial culture after 3 hours, and has the ability to form large and transparent plaques (Fig. 1B) . We attempted to isolate lysogens of Abp1 by recovery of colonies from the middle of plaques after incubation for one week. However, 10 of the tested colonies were still sensitive to Abp1, suggesting that they are not lysogens. Abp1 is a member of the Podoviridae family, it has a short tail and regular icosahedral head about 60-70 nm diameter. (Fig. 1C) . A. baumannii AB1 resistance to Abp1 occurs at a frequency of 3.51±0.46×10 -8 .
Phage stability
As shown in Fig. 2A , Abp1 is relatively thermostable, with high survival rates after incubation at 50 °C. However, only 0.01% of phage were viable after 1 h incubation at 60 °C, after incubation for 15 min at 70 or 80 °C, almost no phage survive. These results demonstrate that Abp1 retains activity well above 37 °C, which simplifies its storage and delivery. As shown in 
Cytotoxicity of Abp1 to HeLa and THP-1 cells
Potential cytotoxic effects of Abp1 were evaluated using HeLa and THP-1 cell assays (Fig. 3) . No cytotoxicity was detected at concentrations of 10 6 , 10 8 , or even 10 10 PFU/ml, in comparison to the negative PBS group. This suggests that Abp1 is safe for use in antimicrobial treatment in vivo.
Killing of AB1 as a function of Abp1 MOI
To determine the effective dose range of Abp1, AB1 was infected with phage over a range of MOI, and cultures were monitored for lysis (OD at 600 nm). As expected, OD increased steadily during the 8-hour period in the negative control (Fig. 4) , but decreased significantly in the cultures infected by Abp1. AB1 growth was inhibited at all MOIs, at the highest phage concentration (MOI=100), AB1 failed to grow, and cultures began to decline at an early stage. After slight increases, AB1 growth eventually declined at MOI of 10, 1, and 0.1, with higher phage concentrations resulting in more rapid lysis. Cultures at all four MOI declined to the same OD 600 level after 5 hrs incubation.
Protection of HeLa cells against AB1 infection
After co-incubation with Abp1 for 24 hours, viable HeLa cell counts were identical to those in the negative control (Fig. 5) , consistent with the HeLa cell toxicity assay described above. In contrast, the viability of HeLa cells infected with AB1 only for 24 hours decreased significantly. When HeLa cells were treated with phage 2 hours after infection by AB1, their Fig. 3 . Cellular cytotoxicity of Abp1. HeLa and THP-1 cells were exposed to various concentrations of Abp1 for 24 hours. Viability (determined using trypan blue) was determined in three independent experiments and is shown as mean±standard deviation. ****P<0.0001 and ***P<0.001 indicate significant differences compared with the PBS treated group. 
Therapeutic application of Abp1 in a local infection
To investigate the effect of phage therapy on local infection, we devised an A. baumannii infection mouse model. As shown in Fig. 6, 3 and 7 days post-infection, wound sizes in animals receiving locally applied phage were significantly smaller than in mice receiving either systemically administered phage or no treatment (negative control). Although systemic phage therapy was associated with reduced wound size relative to the negative control, the difference was not significant. Interestingly, the wounds in mice receiving locally administered phage had a drier and cleaner appearance than wounds in the other two groups (data not shown). These results suggest that local Abp1 therapy has the potential to be used clinically in the control of local infections by multi-drug resistant A. baumannii, and demonstrate that the treatment accelerates wound healing.
Therapeutic application of Abp1 in systemic infection
In addition to testing the efficacy of Abp1 treatment in local infections, we also tested Abp1 in a systemic AB1 infection model. As shown in Fig. 7A , infected mice receiving no treatment succumbed rapidly. Six mice died 8 hours after infection, with an additional 6 dying during the first day. Only 1 mouse in this group survived the entire seven-day observation period. In contrast, all mice treated with phage or polymyxin B survived the entire 7 days of the observation period. In untreated mice, livers and kidneys contained high bacterial loads, while mice treated with phage or polymyxin B contained almost no bacteria in these organs 7 CFU AB1 for 2 hours, and then Abp1 phage (10 8 PFU) were added to the culture medium (AB1+phage). Controls were infected by AB1 but not treated with phage (AB1), uninfected by AB1 but treated with phages (Phage), or both uninfected and untreated (Neg.). Viable cells were counted after incubation for 22 hours. Data are from triplicate experiments. *P<0.05 indicates significant difference between AB1 cells with or without phage treatment. (Fig. 7B) . Finally, in phage-treated animals, phage were detected in both livers and kidneys (approximately 10 4 to 10 5 PFU/g), suggesting that phage replication occurred in vivo (Fig.  7C) . Together, these data suggest that Abp1 is highly effective against systemic A. baumannii infection.
Discussion
Because of increasing drug resistance, A. baumannii has become a serious threat to human health [15] . Phages, as "our enemy's enemy," are potential weapons against drugresistant pathogens [16, 17] . Some phage products have already been approved by the FDA as food biopreservatives, such as ListShield and ListexP100 [18] . The Phagoburn clinical study, supported by several European countries, was conducted to assess the safety, effectiveness, and pharmacodynamics of two therapeutic phage cocktails to treat E. coli and P. aeruginosa burn wound infections [19] . In our previous survey, we found that A. baumannii was highly prevalent in our hospital, and a majority of isolates exhibited multi-drug resistance or pan-drug resistance [20, 21] . To explore the possibility that phage therapy might be effective against this pathogen, we isolated 21 A. baumannii phage strains from the hospital environment. Although nearly all had narrow host ranges, Abp1 exhibited a relatively wide host range. About 5 percent of over 200 clinical A. baumannii isolates are sensitive to Abp1 (data not shown). We also tested several phage cocktails, but the cocktail host range was the simple sum of the phage component host ranges. In our future work, we want to expand the host range by two ways. Firstly, isolate more phages against A. baumannii strains belonging to different ST types. Secondly, explore CRISPR-Cas9 technology to manipulate the phage tails which play an important role in recognizing host receptors.
The results presented here show that Abp1 has several qualities that are desirable for a potential antimicrobial agent. Abp1 is stable under a wide range of temperatures and pH environments, and has almost no detectable toxicity against HeLa or THP-1 cells. In addition, the A. baumannii isolate we used in our work exhibits phage resistance at very low levels, and lysogeny is rare or perhaps nonexistent. Abp1 can lyse nearly all cells even at low MOI, suggesting that a small number of phage may be sufficient for effective phage therapy.
In the wound infection model, topically applied Abp1 accelerated the healing of AB1-infected wounds. However, when phage are introduced systemically via subcutaneous injection, the effect is indistinguishable from the negative control. This result indicates that topical administration is a better choice for the treatment of local infections. In the systemic infection model, phage-treated animals exhibited a 100% survival rate when phage are introduced immediately after bacterial infection. Abp1 efficacy is equivalent to that of polymyxin B (10 mg/kg), and phage therapy is therefore a potential treatment for pan-drug resistant A. baumannii infections.
Conclusion
We have evaluated the safety, effectiveness, and methods of administration for Abp1 in the treatment of A. baumannii local and systemic infections. Our results provide evidence that phage therapy can be effective against multi-drug resistant A. baumannii infections, and suggest that additional clinical studies are warranted to confirm and expand these findings.
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